DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Acular (Ketorolac Tromethamine Ophthalmic) - News

 
 



News related to Acular (Ketorolac Ophthalmic) and/or conditions it is approved for

Increased macular pigment may improve outdoor vision
Source: Eye Health / Blindness News From Medical News Today [2014.08.27]
Individuals with greater amounts of yellow pigment in the eye may be better able to see distant objects in hazy conditions, suggests a study in the September issue of Optometry and Vision Science...

European Commission grants EYLEA licence for the treatment of visual impairment due to diabetic macular oedema
Source: Eye Health / Blindness News From Medical News Today [2014.08.13]
Bayer HealthCare today announces that EYLEA® (aflibercept solution for injection) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular...

Age-related macular degeneration occurs much earlier than previously assumed
Source: Eye Health / Blindness News From Medical News Today [2014.07.22]
It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries.

Macular Degeneration
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2014.01.23]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 6:05:00 PM
Last Editorial Review: 1/23/2014 12:00:00 AM

Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.

'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010

Ruboxistaurin (RBX) may reduce risk of vision loss in diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
Phase III trial demonstrates ruboxistaurin (RBX) may reduce the risk of vision loss especially in diabetic macular edema.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014